Why ImageneBio, Inc.’s (IMA) Stock Is Up 5.68%
As of Thursday, September 17, ImageneBio, Inc.’s IMA share price has surged by 5.68%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Commentary & Analysis
Why ImageneBio, Inc.’s (IMA) Stock Is Up 5.18%
As of Wednesday, September 16, ImageneBio, Inc.’s IMA share price has surged by 5.18%, which has investors questioning if this is right time to sell.Michael Rose
Why ImageneBio, Inc.’s (IMA) Stock Is Up 8.76%
As of Tuesday, September 08, ImageneBio, Inc.’s IMA share price has surged by 8.76%, which has investors questioning if this is right time to sell.Jenna Brashear
Why ImageneBio, Inc.’s (IMA) Stock Is Down 5.81%
As of Monday, August 31, ImageneBio, Inc.’s IMA share price has dipped by 5.81%, which has investors questioning if this is right time to buy.Michael Rose
Why ImageneBio, Inc.’s (IMA) Stock Is Up 5.63%
As of Wednesday, August 19, ImageneBio, Inc.’s IMA share price has surged by 5.63%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | IMA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $53.6 | $257.9 | 16% |
|
| Shares Out (Mil) | 16.2 | 54.3 | 27% |
|
| Institutional Ownership | 93.1% | 92.9% | 62% |
|
| Float (Mil) | 5.8 | 41.4 | 13% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 20 | 674 | 20% |
|
| Price Change (52-week) |
(41.0%) | 51.5% | 22% |
|
| Growth | IMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.847) | ($3.310) | ($4.310) | |
| Month Ago EPS | ($0.847) | ($3.310) | ($4.310) | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($1.235) | ($4.480) | ($3.980) | |
| Year/Year Chg | 34.4% | (65.7%) | (50.6%) | |
| Financials | IMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($53) | ($43) | 16% |
|
| EPS (TTM) | ($4.813) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($53) | ($32) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $89 | $2 | 76% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($68) | $174 | 1% |
|
| Valuation | IMA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.37 | 2.51 | 6% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IMA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (61.3%) | (47.7%) | 10% |
|
| ROE | 183.4% | (54.9%) | 98% |
|
| Liabilities to Assets | 6.6% | 29.1% | 3% |
|
| F-Score | 1 | 3 | na |
|
ImageneBio, Inc. did not pass any screens on 9/25/2026.
